Integrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation
Open Access
- 6 October 2025
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-13
Abstract
It is important to understand the key factors affecting the pharmacokinetics (PK), pharmacological response and toxicity of a drug to ensure clinical therapeutic efficacy and safety across disease populations. Traditionally, label dose-adjustment recommendations for patient populations are based on drug plasma concentrations. However, plasma PK may not be an appropriate surrogate for response and/or toxicity for drugs like statins with intracellular targets and tissue distribution influenced by membrane transporters. This study presents the integration of a physiologically-based pharmacokinetic model with a quantitative systems pharmacology and toxicology (PBPK-QSP-TOX) model for statins in patients with normal kidney function and in different stages of chronic kidney disease (CKD). The QSP model was informed by 2753 measurements of circulating LDL concentrations in 1147 patients (NCT00654537). The TOX model was informed by a meta-analysis of creatine kinase elevation incidence per statin dose in 30 clinical studies (49,284 patients). The CKD populations accounted for disease related changes to 1) anatomy and physiology, 2) drug enzymes and transporters expression and 3) lipoprotein metabolism. This study provides a qualified PBPK-QSP-TOX model for statins that accurately describe plasma concentration–time profiles, lipid-lowering effect and myotoxicity risk over investigated dose range for patients with normal kidney function and varying degree of CKD. Graphical AbstractKeywords
Funding Information
- Uppsala University
This publication has 66 references indexed in Scilit:
- The evolving role of statins in the management of atherosclerosisJACC, 2000
- HMG-CoA Reductase Inhibitors and MyotoxicityDrug Safety, 2000
- HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials dataAtherosclerosis, 1998
- Impaired metabolism of high density lipoprotein in uremic patientsKidney International, 1992
- Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal ImpairmentThe Journal of Clinical Pharmacology, 1992
- Biotransformation of pravastatin sodium in humans.Drug Metabolism and Disposition, 1991
- Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemiaClinical Pharmacology & Therapeutics, 1990
- Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.British Journal of Clinical Pharmacology, 1990
- Regulation of the mevalonate pathwayNature, 1990
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988